BR112017014842A2 - composição de agente de formação de imagem, kit de agente de formação de imagem, e, método para preparação de uma composição de agente de formação de imagem - Google Patents

composição de agente de formação de imagem, kit de agente de formação de imagem, e, método para preparação de uma composição de agente de formação de imagem

Info

Publication number
BR112017014842A2
BR112017014842A2 BR112017014842A BR112017014842A BR112017014842A2 BR 112017014842 A2 BR112017014842 A2 BR 112017014842A2 BR 112017014842 A BR112017014842 A BR 112017014842A BR 112017014842 A BR112017014842 A BR 112017014842A BR 112017014842 A2 BR112017014842 A2 BR 112017014842A2
Authority
BR
Brazil
Prior art keywords
imaging agent
agent composition
preparing
kit
composition
Prior art date
Application number
BR112017014842A
Other languages
English (en)
Inventor
Xu Le-Cun
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of BR112017014842A2 publication Critical patent/BR112017014842A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Studio Devices (AREA)

Abstract

a presente revelação se refere a formulações de agente de formação de imagem, métodos para preparação de formulações de agente de formação de imagem e métodos para utilização delas. a presente revelação também se refere a kits para formulações de agente de formação de imagem.
BR112017014842A 2015-01-11 2016-01-08 composição de agente de formação de imagem, kit de agente de formação de imagem, e, método para preparação de uma composição de agente de formação de imagem BR112017014842A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562102036P 2015-01-11 2015-01-11
US201562171670P 2015-06-05 2015-06-05
PCT/US2016/012653 WO2016112293A1 (en) 2015-01-11 2016-01-08 Cancer imaging agent

Publications (1)

Publication Number Publication Date
BR112017014842A2 true BR112017014842A2 (pt) 2018-01-09

Family

ID=56356476

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014842A BR112017014842A2 (pt) 2015-01-11 2016-01-08 composição de agente de formação de imagem, kit de agente de formação de imagem, e, método para preparação de uma composição de agente de formação de imagem

Country Status (7)

Country Link
US (1) US20170368208A1 (pt)
EP (1) EP3242556A1 (pt)
JP (1) JP2018507179A (pt)
CN (1) CN107427009A (pt)
BR (1) BR112017014842A2 (pt)
CA (1) CA2973380A1 (pt)
WO (1) WO2016112293A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111157638A (zh) * 2019-12-31 2020-05-15 济南康和医药科技有限公司 一种检测维生素c中草酸含量的方法
CN111141736B (zh) * 2019-12-31 2022-07-29 佛山市南海北沙制药有限公司 一种鉴别2-氯喹噁啉的检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3538221B2 (ja) * 1993-11-19 2004-06-14 富士写真フイルム株式会社 定着濃厚液およびそれを用いたハロゲン化銀写真感光材料の処理方法
NZ598145A (en) * 2009-07-31 2014-10-31 Endocyte Inc Folate-targeted diagnostics and treatment
US20120322741A1 (en) * 2010-02-25 2012-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using

Also Published As

Publication number Publication date
WO2016112293A1 (en) 2016-07-14
JP2018507179A (ja) 2018-03-15
CA2973380A1 (en) 2016-07-14
EP3242556A1 (en) 2017-11-15
US20170368208A1 (en) 2017-12-28
CN107427009A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
BR112017010874A2 (pt) composição para impressão tridimensional, composição e objeto tridimensional
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
IL273300A (en) High dose valbenazine formulation and related preparations, methods and kits
EP3208614A4 (en) Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer by using same
BR112017012210A2 (pt) solução conservante de célula, uso da mesma e método de produção de solução conservante de célula
BR112016017584A2 (pt) Composições de nanotribologia e métodos relacionados incluindo nanofolhas moleculares
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
BR112015032526A2 (pt) composições anticaspa e métodos de uso das mesmas
CL2016000351A1 (es) Método para la cuantificación de actinio-227 en composiciones de radio-223.
EP3438194A4 (en) PROCESS FOR PRODUCING POLYMER COMPOSITION CONTAINING CARBOXYL GROUPS
MX2019010492A (es) Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado.
PE20181137A1 (es) Metodos moleculares de aseguramiento de la calidad para su uso en la secuenciacion
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EP3504546A4 (en) MARKER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
SG11202012762WA (en) Methods and compositions for cluster generation by bridge amplification
EP3300501A4 (en) NOVEL COMPOSITIONS, USES THEREOF AND PREPARATION METHODS
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов
EP3242956A4 (en) Methods and compositions for diagnosing bacterial vaginosis
BR112017002139A2 (pt) ?método para preparar um composto?
BR112016016672A2 (pt) Uso de uma composição
EP3530276A4 (en) KIT FOR PREPARING DISEASE THERAPEUTIC AGENT, AND DISEASE THERAPEUTIC AGENT AND MANUFACTURING METHOD THEREOF
BR112017014842A2 (pt) composição de agente de formação de imagem, kit de agente de formação de imagem, e, método para preparação de uma composição de agente de formação de imagem
IT201700016964A1 (it) Composizione per la tosse
BR112017027721A2 (pt) formulação de alta concentração

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 3A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2506 DE 15-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.